acarbose + vildagliptin

Acarbose + vildagliptin is a combination of two oral antidiabetic agents used in the management of type 2 diabetes mellitus. Acarbose is an alpha-glucosidase inhibitor that delays the digestion and absorption of carbohydrates in the intestine, thereby reducing postprandial blood glucose spikes. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases endogenous incretin levels (GLP-1 and GIP), enhancing glucose-dependent insulin secretion and suppressing inappropriate glucagon release. The combination targets complementary mechanisms to improve glycemic control, with acarbose acting primarily on carbohydrate absorption and vildagliptin modulating pancreatic hormone secretion. Clinical studies have shown that this combination effectively reduces HbA1c, fasting plasma glucose, and postprandial plasma glucose levels in patients with type 2 diabetes who are inadequately controlled on monotherapy or dual therapy[6]. Both drugs also exhibit pleiotropic effects such as modulation of gut microbiota[3]. The safety profile includes gastrointestinal side effects from acarbose (e.g., flatulence, diarrhea) and generally good tolerability for vildagliptin[1][5][6].

Other names

vildagliptin + acarbose